Quick Answer
Disc Medicine, Inc. reported R&D Expense of $170.64 million for fiscal year 2025.
Disc Medicine, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $170.64M | +76.5% |
| 2024 | $96.67M | +39.6% |
| 2023 | $69.26M | +107.1% |
| 2022 | $33.44M | +32.8% |
| 2021 | $25.17M | -10.6% |
| 2020 | $28.17M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $50.33M | +103.9% | +8.7% |
| June 30, 2025 | $46.32M | +97.2% | +66.8% |
| March 31, 2025 | $27.76M | +17.1% | +12.5% |
| September 30, 2024 | $24.68M | +71.2% | +5.1% |
| June 30, 2024 | $23.48M | +94.1% | -0.9% |
| March 31, 2024 | $23.70M | +17.5% | +64.4% |
| September 30, 2023 | $14.42M | +82.8% | +19.2% |
| June 30, 2023 | $12.10M | +56.9% | -40.0% |
- Disc Medicine, Inc. showed an increase of +76.5% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Disc Medicine, Inc.’s r&d expense has grown by 505.8% (from $28.17 million to $170.64 million).
- The most recent figure is from Disc Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: